Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...
U.S. stocks are rallying after financial markets worldwide got a shot of adrenaline from an encouraging update on U.S.
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...
Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.
Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...
While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback